Astellas Seeks New Indication For Key Transplant Drug
This article was originally published in PharmAsia News
Japan's Astellas Pharma says it intends to apply for an expanded use for its Prograf (tacrolimus) bone-marrow transplant drug in Japan. The extra indication for the $2 billion-a-year drug would be for treating ulcerative colitis. In addition to its transplant indication, Prograf also has Japanese approval for systemic myasthenia gravis, rheumatoid arthritis and lupus nephritis. (Click here for more
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.